A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
This study will evaluate the lot to lot consistency, safety and immune response of the
 Novartis Meningococcal ACWY conjugate vaccine in healthy US adolescents and adults.
Inclusion Criteria:

 -  Healthy subjects who are 11-55 years of age inclusive and who have given appropriate
 written assent and/or consent

 Exclusion Criteria:

 -  Subjects with a previous or suspected disease caused by N. meningitidis

 -  previous immunization with a meningococcal vaccine or vaccine containing meningococcal
 antigen(s)

 -  previous or suspected disease caused by N. meningitidis

 -  Any serious acute, chronic or progressive disease

 -  Pregnant or breastfeeding